Clinical Trial Update: Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 trial evaluated the Mycobacterial Cell Wall-DNA Complex in patients with non-muscle invasive bladder cancer that is refractory to BC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Mycobacterial Cell Wall-DNA Complex

Snippet

Sponsor: Bioniche Life Sciences Inc. | Conditions: Bladder Neoplasms | Phase 2, Phase 3 | Status: COMPLETED